CD163 and neoplasm: Maliniemi et al reported that indoleamine 2,3-deoxygenase 1, which induces immune tolerance in the tumor microenvironment, is expressed by malignant cells, CD33+ myeloid-derived suppressor cells and CD163+ tumor-associated macrophages in SPTCL.